NCT06916078View on ClinicalTrials.gov

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Liver DysfunctionHealthy
Interventions
DRUG

Lepodisiran

Lepodisiran administered SC

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

78215

RECRUITING

American Research Corporation at Texas Liver Institute, San Antonio

33014-3616

RECRUITING

Clinical Pharmacology of Miami, Miami

H-2143

RECRUITING

CRU Early Phase Unit, Kistarcsa

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY